IXINITY® IXperience story

Situation

IXINITY was launched into a crowded market that was dominated by a much larger competitor and expanding with the introduction of long-acting factor IX products.

Challenge

As a company focused on hemophilia B, Aptevo Therapeutics had very low awareness in the market, and the factor IX product IXINITY offered no major clinical differentiation or pediatric indication.

Insights

The adult hemophilia community feels ignored by big pharma and is skeptical of their “marketing” tactics that don’t address the needs of active, independent patients.

Opportunities

Supported by credible, real-life patient ambassadors, the clinical benefits and associated IXINITY IXperiential support programs are positioned specifically for the needs of active patients.

Let’s Create Your Experience

We’re ready to show you how our combination of behavioral science, brand building, and connected experiences works for your brand.

LET"S TALK